Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis
An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days
Sponsor: Promius Pharma, LLC
Listed as NCT01714544, this PHASE4 trial focuses on Psoriasis and remains completed. Sponsored by Promius Pharma, LLC, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Promius Pharma, LLC
For direct contact, visit the study record on ClinicalTrials.gov .